摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4,5-triethoxy-benzonitrile

中文名称
——
中文别名
——
英文名称
3,4,5-triethoxy-benzonitrile
英文别名
3.4.5-Triaethoxy-benzoesaeure-nitril;3,4,5-Triaethoxy-benzonitril;3,4,5-triethoxybenzonitrile
3,4,5-triethoxy-benzonitrile化学式
CAS
——
化学式
C13H17NO3
mdl
MFCD17616757
分子量
235.283
InChiKey
CQGBUSPSKKLRJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    17
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.461
  • 拓扑面积:
    51.5
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS<br/>[FR] NAPHTYRIDINES SUBSTITUÉES ET LEUR UTILISATION COMME INHIBITEURS DE SYK KINASE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2011092128A1
    公开(公告)日:2011-08-04
    The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.
    该发明涉及公式(1)的新取代萘啉衍生物,以及其药理学上可接受的盐、对映体、非对映体异构体、立体异构体、水合物或溶剂化合物,其中R1从-O-R3或-NR3R4中选择,R3是C1-6-烷基,其被R5和R6取代,R5从氢、支链或直链C1-6-烷基、C2-6-烯基、-C1-6-烷基-氧-C1-3-烷基、C1-3-卤代烷基中选择,R6是环X,其中n为0或1,公式(I)为单键或双键,其中A、B、D和E分别独立地从CH2、CH、C、N、NH、O或S中选择,环X通过位置A、B、D或E连接到分子上,其中所述环X可以选择性地进一步被一个、两个或三个残基取代,每个残基分别从-氧化物、羟基、-C1-3-烷基、-C1-3-卤代烷基、-O-C1-3-烷基、-C1-3-醇基和卤素组成的群中选择,R4、R2、R7、R8、R9、R10、R11和Q的含义可以如权利要求1中所述,以及含有这些化合物的药物组合物。
  • SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS
    申请人:Hoffmann Matthias
    公开号:US20120028939A1
    公开(公告)日:2012-02-02
    The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R 1 is selected from among —O—R 3 or —NR 3 R 4 , R 3 is C 1-6 -alkyl which is substituted by R 5 and R 6 , R 5 is selected from hydrogen, branched or linear C 1-6 -alkyl, C 2-6 -alkenyl, —C 1-6 -alkylen-O—C 1-3 -alkyl, C 1-3 -haloalkyl, R 6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH 2 , CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C 1-3 -alkyl, —C 1-3 -haloalkyl, —O—C 1-3 -alkyl, —C 1-3 -alkanol and halogen, and wherein R 4 , R 2 , R 7 , R 8 , R 9 , R 10 , R 11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.
    该发明涉及公式1的新取代萘啉类化合物,以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物,其中R1从—O—R3或—NR3R4中选择,R3是经R5和R6取代的C1-6烷基,R5从氢、支链或直链C1-6烷基、C2-6烯基、—C1-6烷基氧基-C1-3烷基、C1-3卤代烷基中选择,R6是环X,其中n为0或1,为单键或双键,A、B、D和E各自独立地从CH2、CH、C、N、NH、O或S中选择,环X通过位置A、B、D或E连接到分子,所述环X可以选择地进一步由氧代、羟基、—C1-3烷基、—C1-3卤代烷基、—O—C1-3烷基、—C1-3烷醇和卤素中的每个单独选择的一个、两个或三个残基取代,并且R4、R2、R7、R8、R9、R10、R11和Q可以具有如权利要求1中所给出的含义,以及含有这些化合物的药物组合物。
  • SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2528915A1
    公开(公告)日:2012-12-05
  • US8969568B2
    申请人:——
    公开号:US8969568B2
    公开(公告)日:2015-03-03
  • US9187478B2
    申请人:——
    公开号:US9187478B2
    公开(公告)日:2015-11-17
查看更多